JP2017534613A - デクスメデトミジン製剤を使用する睡眠障害の予防または治療 - Google Patents

デクスメデトミジン製剤を使用する睡眠障害の予防または治療 Download PDF

Info

Publication number
JP2017534613A
JP2017534613A JP2017520539A JP2017520539A JP2017534613A JP 2017534613 A JP2017534613 A JP 2017534613A JP 2017520539 A JP2017520539 A JP 2017520539A JP 2017520539 A JP2017520539 A JP 2017520539A JP 2017534613 A JP2017534613 A JP 2017534613A
Authority
JP
Japan
Prior art keywords
insomnia
dexmedetomidine
sleep
treatment
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017520539A
Other languages
English (en)
Japanese (ja)
Inventor
ネギ，ハルシュ
サイニ，ディーパ
シャルマ，サマー
ナンダバラン，クリシュナン
ヨッカ，フランク
Original Assignee
バイオエクセル コーポレーション
バイオエクセル コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイオエクセル コーポレーション, バイオエクセル コーポレーション filed Critical バイオエクセル コーポレーション
Publication of JP2017534613A publication Critical patent/JP2017534613A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2017520539A 2014-10-15 2015-10-15 デクスメデトミジン製剤を使用する睡眠障害の予防または治療 Pending JP2017534613A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462064205P 2014-10-15 2014-10-15
US62/064,205 2014-10-15
PCT/US2015/055828 WO2016061413A1 (en) 2014-10-15 2015-10-15 Prevention or treatment of sleep disorders using dexmedetomidine formulation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021025810A Division JP2021080276A (ja) 2014-10-15 2021-02-22 デクスメデトミジン製剤を使用する睡眠障害の予防または治療

Publications (1)

Publication Number Publication Date
JP2017534613A true JP2017534613A (ja) 2017-11-24

Family

ID=55747372

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2017520539A Pending JP2017534613A (ja) 2014-10-15 2015-10-15 デクスメデトミジン製剤を使用する睡眠障害の予防または治療
JP2021025810A Pending JP2021080276A (ja) 2014-10-15 2021-02-22 デクスメデトミジン製剤を使用する睡眠障害の予防または治療
JP2023034704A Pending JP2023076465A (ja) 2014-10-15 2023-03-07 デクスメデトミジン製剤を使用する睡眠障害の予防または治療
JP2025030902A Pending JP2025092508A (ja) 2014-10-15 2025-02-28 デクスメデトミジン製剤を使用する睡眠障害の予防または治療

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021025810A Pending JP2021080276A (ja) 2014-10-15 2021-02-22 デクスメデトミジン製剤を使用する睡眠障害の予防または治療
JP2023034704A Pending JP2023076465A (ja) 2014-10-15 2023-03-07 デクスメデトミジン製剤を使用する睡眠障害の予防または治療
JP2025030902A Pending JP2025092508A (ja) 2014-10-15 2025-02-28 デクスメデトミジン製剤を使用する睡眠障害の予防または治療

Country Status (5)

Country Link
US (3) US20170239221A1 (enExample)
EP (1) EP3206685B1 (enExample)
JP (4) JP2017534613A (enExample)
MA (1) MA41689A (enExample)
WO (1) WO2016061413A1 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021529756A (ja) * 2018-06-27 2021-11-04 バイオエクセル セラピューティクス，インコーポレイテッド デクスメデトミジンを含むフィルム製剤、及びその作製方法
JP2022540706A (ja) * 2019-07-19 2022-09-16 バイオエクセル セラピューティクス，インコーポレイテッド 鎮静作用のないデクスメデトミジン治療レジメン
JP2024512710A (ja) * 2021-04-02 2024-03-19 ウェストチャイナホスピタル、スーチョワンユニバーシティ ５－ベンジルイミダゾール類化合物並びにその調製方法及び用途
JP2024528151A (ja) * 2021-08-23 2024-07-26 イーチャン・ヒューマンウェル・ファーマシューティカル・カンパニー・リミテッド デクスメデトミジン経皮組成物、経皮貼付剤及びその調製方法、適用
KR20240169978A (ko) * 2023-05-25 2024-12-03 가톨릭대학교 산학협력단 상추 추출물 및 대추 추출물을 유효성분을 함유하는 불면증 해소용 구강 붕해 필름 조성물

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3562486B1 (en) 2016-12-31 2024-03-13 Bioxcel Therapeutics, Inc. Use of sublingual dexmedetomidine for the treatment of agitation
CN118948739A (zh) * 2020-06-08 2024-11-15 四川普锐特药业有限公司 右美托咪定滴鼻剂或鼻喷剂在助眠药物制备中的应用
CA3212160A1 (en) 2021-03-19 2022-09-22 Johanna KUJALA Tasipimidine formulations and use thereof
AU2023313031A1 (en) 2022-07-27 2024-12-19 Universität Zürich Dexmedetomidine for the treatment of sleep disorders
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens
CN117771220B (zh) * 2024-02-28 2024-05-28 山东第二医科大学 一种右美托咪定中药多糖口溶膜剂及其制备方法和应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009526829A (ja) * 2006-02-13 2009-07-23 サミット コーポレイション パブリック リミティド カンパニー 流涎症の治療のためのアルファ−２受容体アゴニスト（クロニジン）と抗ムスカリン剤（オキシブチニン）との組み合わせ
JP2010516684A (ja) * 2007-01-22 2010-05-20 ターガセプト・インコーポレイテッド メタニコチンアナログの鼻腔内、バッカル、または舌下投与
US20100196286A1 (en) * 2008-12-01 2010-08-05 Armer Thomas A Inhalation delivery methods and devices
JP2011506337A (ja) * 2007-12-07 2011-03-03 シェーリング−プラウ ヘルスケア プロダクツ，インコーポレイテッド 経粘膜吸収のためのフェニレフリンの医薬調合物および医薬組成物
JP2012526854A (ja) * 2009-05-15 2012-11-01 レクロ・ファーマ・インコーポレイテッド デクスメデトミジンの舌下組成物およびその使用方法
WO2015054059A2 (en) * 2013-10-07 2015-04-16 Teikoku Pharma Usa, Inc. Methods and compositions for treating attention deficit hyperactivity disorder, anxiety and insomnia using dexmedetomidine transdermal compositions

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7632517B2 (en) * 1997-10-01 2009-12-15 Novadel Pharma Inc. Buccal, polar and non-polar spray containing zolpidem
WO2002089794A1 (en) * 2001-05-07 2002-11-14 Universite Catholique De Louvain Method for treating neuropathic pain and pharmaceutical preparation therefor
US20050222270A1 (en) * 2004-02-26 2005-10-06 Olney John W Prolonged administration of NMDA antagonist drug and safener drug to create improved stable neural homeostasis
CA2580694A1 (en) * 2004-09-23 2006-03-30 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
US7378508B2 (en) * 2007-01-22 2008-05-27 Optimer Pharmaceuticals, Inc. Polymorphic crystalline forms of tiacumicin B
WO2007010242A1 (en) * 2005-07-18 2007-01-25 Imperial College Innovations Limited Use of a noradrenergic agonist, e.g. guanfacine, for the treatment of cognitive disorders
AU2008251370A1 (en) * 2007-05-10 2008-11-20 Novadel Pharma Inc. Anti-insomnia compositions and methods
JP2013516482A (ja) * 2010-01-08 2013-05-13 レクロ・ファーマ，インコーポレーテッド 局所経皮用デクスメデトミジン組成物およびそれらの使用方法
US8241661B1 (en) * 2011-06-24 2012-08-14 Fuisz Richard C Biocompatible film with variable cross-sectional properties
WO2013061161A2 (en) * 2011-10-28 2013-05-02 Green Bcn Consulting Services Sl New combination therapies for treating neurological disorders
JP6268100B2 (ja) * 2011-12-11 2018-01-24 レクロ・ファーマ，インコーポレーテッド 鼻腔内デクスメデトミジン組成物およびその使用方法

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009526829A (ja) * 2006-02-13 2009-07-23 サミット コーポレイション パブリック リミティド カンパニー 流涎症の治療のためのアルファ−２受容体アゴニスト（クロニジン）と抗ムスカリン剤（オキシブチニン）との組み合わせ
JP2010516684A (ja) * 2007-01-22 2010-05-20 ターガセプト・インコーポレイテッド メタニコチンアナログの鼻腔内、バッカル、または舌下投与
JP2011506337A (ja) * 2007-12-07 2011-03-03 シェーリング−プラウ ヘルスケア プロダクツ，インコーポレイテッド 経粘膜吸収のためのフェニレフリンの医薬調合物および医薬組成物
US20100196286A1 (en) * 2008-12-01 2010-08-05 Armer Thomas A Inhalation delivery methods and devices
JP2012526854A (ja) * 2009-05-15 2012-11-01 レクロ・ファーマ・インコーポレイテッド デクスメデトミジンの舌下組成物およびその使用方法
WO2015054059A2 (en) * 2013-10-07 2015-04-16 Teikoku Pharma Usa, Inc. Methods and compositions for treating attention deficit hyperactivity disorder, anxiety and insomnia using dexmedetomidine transdermal compositions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BR.J.CLIN.PHARMACOL., vol. 56, JPN6020040401, 2003, pages 691 - 693, ISSN: 0004371354 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021529756A (ja) * 2018-06-27 2021-11-04 バイオエクセル セラピューティクス，インコーポレイテッド デクスメデトミジンを含むフィルム製剤、及びその作製方法
JP7488201B2 (ja) 2018-06-27 2024-05-21 バイオエクセル セラピューティクス，インコーポレイテッド デクスメデトミジンを含むフィルム製剤、及びその作製方法
JP2024112848A (ja) * 2018-06-27 2024-08-21 バイオエクセル セラピューティクス，インコーポレイテッド デクスメデトミジンを含むフィルム製剤、及びその作製方法
JP2022540706A (ja) * 2019-07-19 2022-09-16 バイオエクセル セラピューティクス，インコーポレイテッド 鎮静作用のないデクスメデトミジン治療レジメン
JP7739256B2 (ja) 2019-07-19 2025-09-16 バイオエクセル セラピューティクス，インコーポレイテッド 鎮静作用のないデクスメデトミジン治療レジメン
JP2024512710A (ja) * 2021-04-02 2024-03-19 ウェストチャイナホスピタル、スーチョワンユニバーシティ ５－ベンジルイミダゾール類化合物並びにその調製方法及び用途
JP2024528151A (ja) * 2021-08-23 2024-07-26 イーチャン・ヒューマンウェル・ファーマシューティカル・カンパニー・リミテッド デクスメデトミジン経皮組成物、経皮貼付剤及びその調製方法、適用
JP7778911B2 (ja) 2021-08-23 2025-12-02 イーチャン・ヒューマンウェル・ファーマシューティカルズ・カンパニー・リミテッド デクスメデトミジン経皮組成物、経皮貼付剤及びその調製方法、適用
KR20240169978A (ko) * 2023-05-25 2024-12-03 가톨릭대학교 산학협력단 상추 추출물 및 대추 추출물을 유효성분을 함유하는 불면증 해소용 구강 붕해 필름 조성물
KR102853305B1 (ko) * 2023-05-25 2025-09-01 가톨릭대학교 산학협력단 상추 추출물 및 대추 추출물을 유효성분을 함유하는 불면증 해소용 구강 붕해 필름 조성물

Also Published As

Publication number Publication date
JP2023076465A (ja) 2023-06-01
JP2025092508A (ja) 2025-06-19
US20170239221A1 (en) 2017-08-24
EP3206685B1 (en) 2024-05-08
WO2016061413A1 (en) 2016-04-21
MA41689A (fr) 2017-08-22
JP2021080276A (ja) 2021-05-27
US20230414572A1 (en) 2023-12-28
US20250099430A1 (en) 2025-03-27
EP3206685A1 (en) 2017-08-23
EP3206685A4 (en) 2018-06-20

Similar Documents

Publication Publication Date Title
US20250099430A1 (en) Prevention or treatment of sleep disorders using dexmedetomidine formulation
TWI833550B (zh) 用於治療激躁之舌下迪美得托咪汀(dexmedetomidine)之用途
EP3284467B1 (en) Nicotine-containing pharmaceutical compositions
CN101534809B (zh) 取代的2-氨基1,2,3,4-四氢化萘在制备预防、减轻和/或治疗各类疼痛的药物中的用途
US20130072532A1 (en) Topical transdermal dexmedetomidine compositions and methods of use thereof
EP2167065A1 (en) Combination therapy for depression
CN103502224A (zh) 氟马西尼络合物、包含该络合物的组合物及其用途
AU2021204517B2 (en) Combination of opioids and n-acylethanolamines
JP2009517393A (ja) 不安症の治療方法
AU2008259864B2 (en) Methods and compositions for administration of Oxybutynin
WO2016061554A1 (en) Synergistic composition of known, safe pharmaceuticals for use in insomnia and a method of treatment thereof
US20220168318A1 (en) Pharmaceutical compositions and methods for treatment of insomnia
EP4478887A1 (en) Novel pharmaceutical compositions and methods for treatment of insomnia
MX2011001631A (es) Tratamiento de transtornos de ansiedad.
CN114585364B (zh) 谷氨酸2b受体拮抗剂和σ受体激动剂作为止咳药的用途
JP6734470B2 (ja) ヒスタミン−３受容体インバースアゴニストとアセチルコリンエステラーゼ阻害剤との組合せ
Yadav et al. Concise review: Therapeutic potential of flupirtine maleate
Chabukswar et al. A REVIEW ON APPLICATIONS OF DEXMEDETOMIDINE (BXCL501) IN CNS DISORDERS
JP2025529123A (ja) 急性ストレス障害を処置するための方法及び組成物
RU2620855C1 (ru) Фармацевтическая композиция для профилактики и лечения нарушений сна
JP2016518406A (ja) 嗜癖障害およびアルコール関連障害を治療するための（＋）−１−（３，４−ジクロロフェニル）−３−アザビシクロ［３．１．０］へキサンの使用
TW200906406A (en) Use of a compound that is a neurokinin A NK2 receptor antagonist for the preparation of medicaments for use in the prevention and treatment of sexual dysfunctions
HK40014031A (en) Use of sublingual dexmedetomidine for the treatment of agitation
US20210128496A1 (en) Dropropizine in combination with ambroxol in the dosage form of syrup or tablets

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170614

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180418

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20181219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20181219

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190625

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190924

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200107

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200406

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200625

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20201022

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210222

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20210222

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20210305

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20210402

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20210405

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20210416

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20210420

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20220120

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20220330

C141 Inquiry by the administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C141

Effective date: 20220330

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20220406

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220615

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20221109

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20221206

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20221206